RxDoctor Payments Data

Kenneth Spiller, MD

Internal Medicine · Lafayette, LANPI 1043220239

Payments from drug & device makers

$1,335in general payments, 2019–2025

Across 84 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$233
  • AbbVie$172
  • Pfizer$139
  • Astellas Pharma US Inc$127
  • Novo Nordisk$86
  • AstraZeneca$64
  • plus $515 from 16 others

What the payments were for

  • Food & beverage$1,335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,335 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$241,886
Medicare patients
499
Services billed
3,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide62$80,193
EliquisApixaban73$63,672
OzempicSemaglutide26$27,066
XareltoRivaroxaban13$15,480
MounjaroTirzepatide13$13,193
MyrbetriqMirabegron23$9,551
LinzessLinaclotide14$7,586
VeozahFezolinetant13$7,196
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$6,290
TradjentaLinagliptin12$6,128
Rivastigmine12$4,842
Atorvastatin Calcium367$3,400
Duloxetine Hcl173$3,246
Levothyroxine Sodium404$3,029
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$2,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$233$93,38575 claims
PfizerEliquis$139$63,67273 claims
Novo NordiskOzempic$86$27,06626 claims
Astellas Pharma US IncMyrbetriq, Veozah$127$16,74636 claims
Johnson & JohnsonXarelto$26$15,48013 claims
AbbVieLinzess, Synthroid$172$9,82458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →